All Blogs
Apr 30, 2026
Olympus Secures FDA Clearance for POWERSEAL™ Open Extended Jaw Device; Abbott’s Ultreon™ 3.0 Receives FDA Clearance and CE Certification; LTS Broadens CDMO Capabilities with Ophthalmic Drug Delivery Expertise; BD Transforms Central Line Placement with Groundbreaking Technology; AI Models Deliver Up to 73% Fewer Genome Analysis Errors in New Research; Calidar Finishes Enrollment in First-in-Human Trial of 4D Mammography System
Olympus Received FDA Clearance for POWERSEAL™ Open Extended Jaw Device On 28 April 2026, Olympus Corporation announced that it had received 510(k) clearance from the U.S. Food and Drug Administration for its POWERSEAL™ Open Extended Jaw Sealer/Divider for use in open surgical procedures. The approval marke...
Read More...
Apr 29, 2026
Spinal Fusion Devices in Healthcare: Stabilizing the Backbone of Modern Orthopedics
Spinal disorders, ranging from degenerative disc disease to scoliosis, are a leading cause of disability worldwide. As populations age and lifestyles become increasingly sedentary, the burden of chronic back pain continues to rise. In this evolving healthcare landscape, spinal fusion devices have emerged as a corne...
Read More...
Apr 28, 2026
Eli Lilly and Company to Acquire Ajax Therapeutics; Sun Pharma Moves to Acquire Organon in Definitive Agreement; European Commission Approves Novartis RHAPSIDO as First Oral Targeted Therapy for Chronic Spontaneous Urticaria; Tovecimig Delivers Significant Clinical Benefit in COMPANION-002 Phase 2/3 Trial for Biliary Tract Cancer; Arrowhead Pharmaceuticals Receives CHMP Backing for REDEMPLO Approval in Europe for Familial Chylomicronemia Syndrome
Eli Lilly and Company Signs Deal to Acquire Ajax Therapeutics Eli Lilly and Company has entered into a definitive agreement to acquire Ajax Therapeutics, Inc., a biotechnology firm specializing in next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs). The deal is structured with a total potentia...
Read More...
Apr 27, 2026
Breaking the Cycle of Failure in AKI Drug Development: Opportunities in a High-Burden, Underserved Market
Summary AKI continues to be associated with substantial morbidity and mortality, particularly in hospitalized and ICU-based settings where patients often present with severe underlying illness. TERLIVAZ (terlipressin) is the only approved pharmacologic therapy in the broader AKI space, receiving US FDA...
Read More...
Apr 24, 2026
The gMG Treatment Gold Rush: Key Companies Racing Toward Breakthrough Launches by 2036
Summary Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder, with ~195,000 diagnosed patients across seven major markets in 2025, projected to reach ~250,000 by 2036. Despite recent approvals of FcRn blockers and complement inhibitors, major unmet needs remain, including unpred...
Read More...
Apr 23, 2026
Utepreva Announces FDA 510(k) Clearance for Endometrial Sampler Aimed at Early Cancer Detection; Sonorous Neurovascular Announces FDA 510(k) Clearance of BosCATH Neurovascular Catheter; OrganaBio and RxMP Therapeutics Partner to Support Manufacturing of RMP-402 Hemostatic Therapy; RhythMedix Introduces the New RhythmStar® SL Advanced Cardiac Monitor; Nicklaus Children’s Hospital Achieves First Traveling Bedside PDA Closure in Fort Lauderdale NICU; RIVANNA Advances Multi-center Clinical Study of Accuro XV Musculoskeletal Imaging System
Utepreva Introduced FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer On 22 April 2026, Utepreva LLC announced the launch of the Utepreva Endometrial Sampler, a patented, FDA 510(k)-cleared, single-use endometrial sampling device designed to enhance tissue capture a...
Read More...
Apr 22, 2026
8 Applications of Cryoablation Devices in Healthcare
Cryoablation, the use of extreme cold to destroy abnormal tissue, has rapidly evolved from a niche surgical technique into one of the most versatile minimally invasive tools in modern medicine. By precisely delivering temperatures as low as –40°C to –170°C through specialized probes, cryoablation devices destroy ta...
Read More...
Apr 21, 2026
Novo Nordisk Reports Positive Phase 3 Results for Etavopivat in Sickle Cell Disease; UCB to Buy Neurona Therapeutics; KEYTRUDA Regimens Secure FDA Priority Review in Muscle-Invasive Bladder Cancer; Savara Announces FDA Review Extension for Molgramostim in Autoimmune PAP; Terremoto Biosciences Completes $108 Million Series C Financing to Expand AKT1 Inhibitor Development
Novo Nordisk’s Etavopivat Meets Phase 3 Endpoints in Sickle Cell Disease Novo Nordisk announced topline findings from HIBISCUS, a pivotal Phase 3 study evaluating once-daily oral etavopivat in adults and adolescents living with Sickle Cell Disease. The trial met both co-primary endpoints, with etavopivat showing...
Read More...
Apr 20, 2026
Travere Turns Setback into Success with FILSPARI Breakthrough in FSGS
For decades, patients with focal segmental glomerulosclerosis had no approved treatment. Then Travere Therapeutics did the unthinkable: it turned a Phase 3 setback into a historic approval. Imagine being diagnosed with a progressive kidney disease, one that scars your kidneys from the inside, strips proteins fro...
Read More...
Apr 17, 2026
Shaping the Future of Idiopathic Membranous Nephropathy Treatment: Breakthroughs in Targeted Therapies
Summary The epidemiological landscape of IMN highlights a substantial disease burden across the seven major markets. According to DelveInsight’s analysis, IMN accounted for approximately 69,000 prevalent cases in 2025, within a broader pool of nearly 87,000 membranous nephropathy cases. This indicates that IMN ...
Read More...